Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Zhejiang University
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with histologically confirmed advanced pancreatic cancer who had experienced progression during first-line gemcitabine and S-1 were eligible for enrollment on this open-label, randomized study.
Measurable reference cancer site(s) confirmed with computed tomography (CT) or magnetic resonance imaging (MRI)
Karnofsky performance status (KPS) of at least 70%
-Adequate renal function, adequate hepatic function, adequate bone marrow function
You may not be if
The presence of any severe concomitant disease that could interrupt the planned treatment; intractable pain
Hypersensitivity to study drugs
Serious cardiovascular disease (eg, unstable coronary artery disease or myocardial infarction within 4 weeks of study start)
National Cancer Institute CommonToxicity Criteria grade 3 or 4 sensory or motor neuropathy
Prior or concurrent malignancy (other than pancreatic cancer)
Female, pregnancy or breastfeeding.
Clareo Health | Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer
